By:
On:
In: Health
With: 1 Comment

On Monday, the U.S. Food and Drug Administration (FDA) reissued the emergency use authorizations (EUAs) for Eli Lilly’s bamlanivimab-etesevimab (administered together) and Regeneron’s REGEN-COV (casirivimab and imdevimab) monoclonal antibody treatments, which states these treatments are not authorized for use in any U.S. state, territory, or jurisdiction at this time. FDAContinue Reading